Zai Lab Limited — FY2023 Form 10-K
Reporting period: Fiscal year ended December 31, 2023. This is an annual report, not a standalone fourth-quarter report; quarterly financial results are not clearly provided in the supplied filing text. Figures below are in U.S. dollars unless stated otherwise.
Business context
Zai Lab is a Cayman Islands holding company and commercial-stage biopharmaceutical business with substantial operations in Greater China and the United States. Its focus areas are oncology, autoimmune disorders, infectious disease, and neuroscience. Five products were marketed in Greater China during 2023: ZEJULA, OPTUNE, QINLOCK, NUZYRA, and VYVGART. The company depends substantially on licensed products, third-party suppliers, and distributors.
Financial performance and liquidity
| Metric | FY2023 | FY2022 | Change |
|---|---|---|---|
| Net product revenue | $266.7 million | $212.7 million | +25% |
| Total revenue | $266.7 million | $215.0 million | +24% |
| Cost of sales | $95.8 million | $74.0 million | +29% |
| Gross profit and margin | $170.9 million; 64.1% | $138.7 million; 64.5% | Margin down about 0.4 percentage points |
| Research and development expense | $265.9 million | $286.4 million | −7% |
| Selling, general and administrative expense | $281.6 million | $259.0 million | +9% |
| Loss from operations | $366.6 million | $404.4 million | Loss narrowed |
| Net loss | $334.6 million | $443.3 million | Loss narrowed 25% |
| Net loss per ordinary share / ADS | $0.35 / $3.46 | $0.46 / $4.63 | Loss per share narrowed |
| Net cash used in operating activities | $198.2 million | $367.6 million | Cash use decreased |
Net revenue by product was ZEJULA $168.8 million (+16%), OPTUNE $47.0 million (−1%), QINLOCK $19.2 million (+29%), NUZYRA $21.7 million (+316%), and VYVGART $10.0 million (launched in September 2023). Revenue growth reflected higher sales volumes and VYVGART’s launch, partly offset by distributor rebates and market disruption associated with China’s healthcare-sector anti-corruption enforcement efforts.
At year-end, cash and cash equivalents were $790.2 million, short-term investments $16.3 million, and restricted cash $1.1 million, totaling $807.6 million. Cash, cash equivalents, and restricted cash declined $218.0 million during the year. Total assets were $1.036 billion, total liabilities $240.2 million, and shareholders’ equity $796.1 million. No borrowings are shown on the December 31, 2023 consolidated balance sheet. Management said available cash and investments were expected to fund operating and capital requirements for at least 12 months.
In February 2024, the company entered into facilities allowing subsidiaries to borrow up to approximately $164.5 million for working capital; approximately $54.8 million had been borrowed at the time described in the filing. Zai Lab Limited guaranteed approximately $142.0 million of the facilities. These are subsequent events, not year-end debt balances.
Material changes and notable items
- Revenue increased 24%, while net loss narrowed by $108.7 million. Lower R&D expense, higher interest income, and reduced foreign-currency losses contributed to the improvement.
- R&D expense fell mainly because of lower upfront and milestone license payments; personnel and clinical-trial costs increased. SG&A rose with commercial, rental, administrative, and share-based compensation costs.
- The company recorded a $10.0 million gain from selling intellectual property and related know-how. Foreign-currency loss was $14.9 million, down from $56.4 million in 2022. Interest income rose to $39.8 million.
- Distributor rebates and sales returns were $32.2 million, versus $21.3 million in 2022. Rebates associated with NRDL price reductions were $13.0 million, versus $5.3 million.
- In the fourth quarter, Zai Lab decided to discontinue development of margetuximab and odronextamab and gave notice to terminate the related license agreements. Its partner also de-prioritized BLU-945.
Outlook, management commentary, and risks
Management expects product revenue to continue increasing in 2024, including through expanded NRDL access for VYVGART and NUZYRA. The company’s stated goal is overall corporate profitability by the end of 2025; this is a target, not a guarantee. It expects continued substantial R&D and commercialization spending. Potential future milestone payments include up to $303.5 million for current clinical programs, $673.2 million for other programs, and $2.46 billion in sales-based milestones, plus royalties, all contingent on development or commercial performance.
- Pipeline developments included NMPA acceptance of applications for repotrectinib, sulbactam-durlobactam, and subcutaneous efgartigimod; repotrectinib received priority review. Clinical and regulatory outcomes, timing, and commercialization remain uncertain.
- Key risks include China–U.S. geopolitical and regulatory developments; Chinese data-transfer, cybersecurity, human-genetic-resource, and securities-filing requirements; currency and cash-transfer restrictions; NRDL price reductions; and intensified anti-corruption enforcement in healthcare.
- The company relies on licensors, contract manufacturers, CROs, and a concentrated distributor base. Its five largest customers represented 35.0% of product revenue in 2023; the largest customer represented 19.9%.
- Zai Lab has incurred losses since inception. Management cautions that funding needs could arise sooner than expected despite its stated 12-month liquidity outlook. It reported no material pending legal proceedings and no material cyber incident to date.
Important facts for investors to verify
- Whether 2024 revenue growth and the end-2025 profitability goal remain achievable, considering persistent losses and operating cash use.
- Product-level sales, gross margins, and the effect of NRDL pricing, rebates, reimbursement access, and healthcare-sector enforcement on demand.
- Cash runway and the terms, utilization, guarantees, and repayment obligations of the February 2024 borrowing facilities.
- Clinical, regulatory, and launch milestones for late-stage candidates, particularly repotrectinib, SUL-DUR, and efgartigimod, and any pipeline changes.
- Exposure to China-related data, regulatory, currency-conversion, and cash-repatriation restrictions, plus the status of future CSRC filings that may be required for securities offerings.